Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial
The study will be conducted in compliance with Good Clinical Practices (ICH-GCP) and the Declaration of Helsinki, and in accordance with applicable legal and regulatory requirements, including archiving of essential documents.
Colorectal Cancer Metastatic|Pancreatic Cancer Metastatic
COMBINATION_PRODUCT: Nivolumab plus Ipilimumab plus Maraviroc
Number of participants and severity of treatment-related adverse Events as assessed by CTCAE v4.0, Safety and tolerability of combined Maraviroc, Ipilimumab and Nivolumab, up to 11 days
Progression Free Survival, Progression free survival after initiation of trial medication, time to progression on trial medication, radiologic evaluation based on RECIST and iRECIST criteria, up to 36 months|Overall Survival, Overall survival after initiation of trial medication, radiologic evaluation based on RECIST and iRECIST criteria, up to 36 months|Tissue Response, Detailed evaluation of in-treatment biopsy compared to pre-treatment biopsies, investigating overt tumor cell death, immune cell activation, immune cell density and general markers of proliferation, up to 3 months
A study to evaluate the safety, tolerability and feasibility of treatment with Maraviroc, nivolumab and ipilimumab in layers of colon and pancreatic cancer patients